Matthew Keller
Stock Analyst at HC Wainwright & Co.
(1.01)
# 3,890
Out of 5,090 analysts
10
Total ratings
33.33%
Success rate
-6.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $1.00 | +500.00% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $10.00 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $3.44 | +801.16% | 2 | Sep 30, 2025 | |
| FGEN FibroGen | Reiterates: Buy | $43 | $8.15 | +427.61% | 2 | Sep 24, 2025 | |
| IFRX InflaRx | Assumes: Buy | $6 | $1.11 | +442.99% | 1 | Sep 2, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.87 | +128.72% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.35 | +936.96% | 1 | Aug 15, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $6 | $6.34 | -5.36% | 1 | Aug 14, 2025 |
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $1.00
Upside: +500.00%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $10.00
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $3.44
Upside: +801.16%
FibroGen
Sep 24, 2025
Reiterates: Buy
Price Target: $43
Current: $8.15
Upside: +427.61%
InflaRx
Sep 2, 2025
Assumes: Buy
Price Target: $6
Current: $1.11
Upside: +442.99%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.87
Upside: +128.72%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.35
Upside: +936.96%
Galectin Therapeutics
Aug 14, 2025
Reiterates: Buy
Price Target: $6
Current: $6.34
Upside: -5.36%